Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 11/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PDE1A | P54750 | 2/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PDE8B | O95263 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23210999 | 0.86 | NPBWR1 (0.48) | NPBWR1PKMPKLRMCHR1GRIN1 | |
| SCHEMBL33526059 | 0.77 | GRIN1 (0.55) | GRIN1GRIN2BCYP19A1 | |
| SCHEMBL31752570 | 0.72 | CYP11B2 (0.36) | — | |
| SCHEMBL33526429 | 0.68 | GRIN1 (0.46) | NPBWR1PKMPKLRMCHR1GRIN1 | |
| SCHEMBL3356641 | 0.68 | NPBWR1 (0.49) | NPBWR1PKMPKLRMCHR1CYP19A1 | |
| SCHEMBL16014455 | 0.67 | KMT2A (0.54) | NPBWR1PKMMCHR1PDE8B | |
| SCHEMBL15123353 | 0.67 | CYP19A1 (0.57) | GRIN1GRIN2BCYP19A1MAOAMAOB | |
| SCHEMBL23210845 | 0.66 | GRIN1 (0.61) | NPBWR1MCHR1GRIN1GRIN2B | |
| SCHEMBL23210996 | 0.65 | GRIN1 (0.58) | NPBWR1GRIN1GRIN2BPDE1B | |
| SCHEMBL4313877 | 0.65 | PIK3R1 (0.48) | PKMPKLRGRIN1GRIN2BCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | NPBWR1 48/4885PKM 3636/4885PKLR 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.